title: T cell therapies.
abstract: T cell therapies are increasingly used for the treatment of malignancies and viral-associated diseases. Initial studies focused on the use of unmanipulated T cell populations after allogeneic stem cell transplantation. More recently, the use of antigen-specific T cells has been explored. This chapter reviews the clinical experience with polyclonal Epstein-Barr virus (EBV)-specific cytotoxic T cells (CTL) for the treatment of EBV-associated malignancies. Strategies on how to improve the antitumor activity of EBV-specific CTL are being discussed. If effective, these strategies will have broad implications for T cell therapies for a range of human tumors with defined antigens.
authors.affiliation: Center for Gene and Cell Therapy, Baylor College of Medicine, 6621 Fannin Street MC 3-3320, 77030 Houston, USA. smg@bcm.edu
authors.forename: S
authors.initials: S
authors.lastname: Gottschalk
authors.forename: C M
authors.initials: CM
authors.lastname: Bollard
authors.forename: K C
authors.initials: KC
authors.lastname: Straathof
authors.forename: C U
authors.initials: CU
authors.lastname: Louis
authors.forename: B
authors.initials: B
authors.lastname: Savoldo
authors.forename: G
authors.initials: G
authors.lastname: Dotti
authors.forename: M K
authors.initials: MK
authors.lastname: Brenner
authors.forename: H E
authors.initials: HE
authors.lastname: Heslop
authors.forename: C M
authors.initials: CM
authors.lastname: Rooney
mesh_terms: D000818:Animals; D004854:Herpesvirus 4, Human; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D016219:Immunotherapy, Adoptive; D008232:Lymphoproliferative Disorders / Q000628:therapy; D009303:Nasopharyngeal Neoplasms / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D017735:Virus Latency